Sign In
4 Sep 2012 07:00
NOTIFICATION OF TRANSACTIONS OF DIRECTORS AND APPLICABLE EMPLOYEES
VERNALIS PLC ("the Company")
4 September 2012
Vernalis plc (LSE:VER) announces that a grant of options over ordinary shares of 1p each in the Company was made yesterday to employees under the Savings-Related Share Option Plan.
All employees in the Company were eligible to enter a savings contract and participate in the grant of options.
Options granted to Executive Directors and other applicable employees (for the purposes of the AIM Rules for Companies) who are members of the management committee ("Applicable Employees") were as follows:
Executive Director | No of shares under option | Exercise Price |
Exercise Period | % of Issued Share Capital |
I Garland
|
45,918 |
19.6 pence |
1 Oct 2015 - 31 Mar 2016 |
0.010% |
D Mackney
|
45,918 |
19.6 pence |
1 Oct 2015 - 31 Mar 2016 |
0.010% |
Applicable Employees | No of shares under option | Exercise Price |
Exercise Period | % of Issued Share Capital |
S Pawsey
|
45,918 |
19.6 pence |
1 Oct 2015 - 31 Mar 2016 |
0.010% |
M Wood
|
45,918 |
19.6 pence |
1 Oct 2015 - 31 Mar 2016 |
0.010% |
-- ends --
Enquiries:
Vernalis Contacts: | |
Ian Garland, Chief Executive Officer | +44 (0) 118 938 0015 |
David Mackney, Chief Financial Officer
| |
Nomura Code Securities Limited: | +44 (0) 20 7776 1200 |
Juliet Thompson | |
Jonathan Senior
| |
Brunswick Group: Jon Coles
| +44 (0) 20 7404 5959 |
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan for the acute treatment of migraine and an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough/cold market as well as seven programmes in its NCE development pipeline. Vernalis has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Follow the stocks
